

IN THE CLAIMS:

---

1. (Currently amended) A purified antibody for modulating a biological activity of a malignant cell that expresses a frizzled 5 receptor, wherein said antibody specifically binds to at least one epitope in an extracellular domain of the ~~frizzle~~ frizzled 5 receptor expressed on the malignant cell.
2. (Currently amended) The purified antibody of claim 1, wherein the extracellular domain comprises an amino terminal peptide fragment of the frizzled 5 receptor.
3. (Original) The purified antibody of claim 1 further comprising an antibody fragment having an antigen binding region that specifically binds to the epitope.
4. (Currently amended) The purified antibody of claim 1, wherein the antibody is capable of sensitizing malignant cells expressing the frizzled 5 receptor to a cytotoxic factor.
5. (Currently amended) The purified antibody of claim 1, wherein the antibody inhibits binding of a Wnt ligand to the frizzled 5 receptor.
6. (Original) The purified antibody of claim 1 further comprising a detectable label.
7. (Original) The purified antibody of claim 1, wherein the antibody is a human antibody.
8. (Original) The purified antibody of claim 1, wherein the antibody is a monoclonal antibody.
9. (Original) The purified antibody of claim 1, wherein the antibody binds to a frizzled-2 receptor amino terminal extracellular domain.

10-15. (Cancelled)

16. (Currently amended) A pharmaceutical composition comprising a purified antibody for modulating a biological activity of a malignant cell that expresses a frizzled 5 receptor, wherein said antibody specifically binds to at least one epitope in an extracellular domain of the ~~frizzle~~ frizzled 5 receptor expressed on the malignant cell, in a pharmaceutically acceptable carrier.

17-21. (Cancelled)

E1  
22. (Currently amended) A pharmaceutical composition useful as a vaccine against malignancy for administration to a patient having a predisposition for the malignancy, comprising a purified antibody for modulating a biological activity of a malignant cell that expresses a frizzled 5 receptor, wherein said antibody specifically binds to at least one epitope in an extracellular , domain of the ~~frizzle~~ frizzled 5 receptor expressed on the malignant cell.

23-26. (Cancelled)

27. (New) The purified antibody of claim 1, wherein the frizzled 5 receptor amino terminal extracellular domain has a sequence that is greater than 80% homologous to an amino acid sequence of SEQ ID NO: 68.

---